TY  - JOUR

T1  - Pertuzumab for the Neoadjuvant Treatment of Early-Stage HER2-Positive Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

JO  - Pharmacoeconomics

UR  - https://eprints.whiterose.ac.uk/id/eprint/119850

PY  - 2018/01/01

AU  - Squires H

AU  - Pandor A

AU  - Thokala P

AU  - Stevens JW

AU  - Kaltenthaler E

AU  - Clowes M

AU  - Coleman R

AU  - Wyld L

ED  - 

DO  - DOI: 10.1007/s40273-017-0556-7

PB  - Springer Verlag 

VL  - 36

IS  - 1

SP  - 29

EP  - 38

Y2  - 2025/10/31

ER  -